Capricor Therapeutics CAPR in premarket is trading 18% higher at $7.52 as traders expect positve results from Capricor’s lead candidate, deramiocel (CAP-1002), which is in a pivotal Phase 3 trial (HOPE-3) evaluating its efficacy in treating cardiomyopathy associated with DMD—a progressive muscle-wasting disease with no cure and limited options.
The company (CAPR) announced in early November 2025 that topline results are expected “in the coming weeks,” likely in late fourth quarter 2025. This has sparked a retail frenzy, with traders hailing it as potential “best data” for cardiac outcomes in DMD patients.
An FDA Type A meeting in August 2025 confirmed that positive HOPE-3 data could support resubmission of the Biologics License Application (BLA) for deramiocel, addressing a July 2025 rejection letter that cited insufficient efficacy evidence. Resubmission is targeted for 2026, keeping the BLA open for the cardiomyopathy indication.
Capricor Therapeutics stock has experienced high volatility due to conflicting news, including a recent short-selling call by Martin Shkreli, which initially caused a dip, and subsequent positive sentiment building around the upcoming trial data. High short interest (not quantified in recent data but implied) adds squeeze potential.
CAPR Stock has gained over 42% in the last week while it is 54% lower since the beginning of 2025. From technical view the stock is approaching the critical 100-day simple moving average resistance at $6.68. A convincing close above that barrier might open the way for the next resistance level standing at $9. All in all the trial data will be the most important catalust for the CARP stock price. A trial miss could tank the stock 50%, and biotech dilution (common for cash-burners like Capricor) remains a concern. Third quarter 2025 results showed ongoing losses, with cash runway into 2026.
CAPR Stock Snapshot (as of Dec 3, 2025, premarket)
| Metric | Value | Notes |
|---|---|---|
| Current Price | ~$6.50–$7.50 (+18–25%) | Up from $4.60 52-week low |
| Market Cap | ~$300M | Small-cap biotech volatility |
| 52-Week Range | $4.60–$19.64 | Reflects trial/FDA swings |
| Analyst Target | Up to $20+ (298% upside) | From B. Riley and others |
| Short Interest | Elevated (implied) | Fueling squeeze talk |
Nikolas has been involved in the finance industry for over fifteen years spanning across Europe and USA with a depth of knowledge and experience within many aspects of the financial markets. Nikolas gained several years experience with some of the Europe’s leading Brokers, as equity analyst, and trader managing accounts for both Private and Corporate Investors. He enjoys both the fundamental and technical aspects of trading focusing on stock markets and all FX majors. Currently, Nikolas provides analysis and comments to online financial publications. Educational background in Economics (BSc), and Finance (MSc).
